Highlights Q2 – 2017

Serodus requested a Pre-Investigational New Drug (pre-IND) meeting with the Food and Drug Administration (FDA), USA. The objective is to receive guidance for the development path for the lead compound SER150 in patient with Diabetic Nephropathy. Serodus is proud to announce that the meeting has been granted and will be held ultimo September 2017. The aim of the meeting is to discuss the future development plan in the US for SER150. Similar meeting will be planned in Europe

Close Menu